Clinical Validation of <i>PBRM1</i> Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell CarcinomaDavid A. Braun, Toni K. Choueiri, Yuko Ishii et al.|JAMA Oncology|2019Cited by 243
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical TrialJean‐Christophe Pignon, Sabina Signoretti, David A. Braun et al.|Clinical Cancer Research|2019Cited by 121
Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).Jean‐Christophe Pignon, Sabina Signoretti, Opeyemi A. Jegede et al.|Journal of Clinical Oncology|2019Cited by 10
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).Ziad Bakouny, Toni K. Choueiri, David A. Braun et al.|Journal of Clinical Oncology|2020Cited by 5